EMA has granted orphan drug status to Autolus Therapeutics' acute lymphoblastic leukemia drug CAR T. The status allows to reduce production costs and facilitates the procedure of drug approval. A key advantage is the exclusivity of the drug in the EU for 10 years after EMA approval.